WO2011104307A3 - Ligands for antibody purification by affinity chromatography - Google Patents

Ligands for antibody purification by affinity chromatography Download PDF

Info

Publication number
WO2011104307A3
WO2011104307A3 PCT/EP2011/052758 EP2011052758W WO2011104307A3 WO 2011104307 A3 WO2011104307 A3 WO 2011104307A3 EP 2011052758 W EP2011052758 W EP 2011052758W WO 2011104307 A3 WO2011104307 A3 WO 2011104307A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
affinity chromatography
antibody purification
antibody
protein
Prior art date
Application number
PCT/EP2011/052758
Other languages
French (fr)
Other versions
WO2011104307A2 (en
Inventor
Holger Bittermann
Klaus Burkert
Bernd Kalbfuss-Zimmermann
Oliver Keil
Thomas Neumann
Inge Ott
Kristina Schmidt
Renate Sekul
Original Assignee
Graffinity Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graffinity Pharmaceuticals Gmbh filed Critical Graffinity Pharmaceuticals Gmbh
Publication of WO2011104307A2 publication Critical patent/WO2011104307A2/en
Publication of WO2011104307A3 publication Critical patent/WO2011104307A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3253—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure not containing any of the heteroatoms nitrogen, oxygen or sulfur, e.g. aromatic structures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use, for affinity purification of a protein, of a compound according to the general formula (I), wherein A is selected f The present invention relates to compounds according to the general formula (I), and to their use for affinity purification of a protein. Preferably, the entity to be separated or purified is an antibody, in particular an antibody of the Bevacizumab type or the Ranibizumab type.
PCT/EP2011/052758 2010-02-25 2011-02-24 Ligands for antibody purification by affinity chromatography WO2011104307A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10154750.3 2010-02-25
EP10154750 2010-02-25

Publications (2)

Publication Number Publication Date
WO2011104307A2 WO2011104307A2 (en) 2011-09-01
WO2011104307A3 true WO2011104307A3 (en) 2011-11-03

Family

ID=42244683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/052758 WO2011104307A2 (en) 2010-02-25 2011-02-24 Ligands for antibody purification by affinity chromatography

Country Status (1)

Country Link
WO (1) WO2011104307A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150013435A (en) * 2012-02-08 2015-02-05 그라피니티 파머수티컬스 게엠베하 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY IV
WO2014020152A1 (en) * 2012-08-02 2014-02-06 Graffinity Pharmaceuticals Gmbh Ligands for apheresis and immunoabsorption
WO2014178078A2 (en) * 2013-04-30 2014-11-06 Intas Boipharmaceuticals Limited Novel cloning, expression & purification method for the preparation of ranibizumab
EP3727468A4 (en) * 2017-12-19 2021-09-22 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
US20220267369A1 (en) * 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
CA3118156A1 (en) 2018-12-12 2020-06-18 Purilogics, LLC Affinity membrane and method of preparation
WO2021046284A1 (en) 2019-09-05 2021-03-11 Bio-Rad Laboratories, Inc. Anionic exchange-hydrophobic mixed mode chromatography resins

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE135638C (en) *
DE1126373B (en) * 1957-03-04 1962-03-29 Thiemann Chem Pharm Fab Process for the preparation of salicylamide-O-acetic acid amides
DE1212955B (en) * 1961-12-06 1966-03-24 Thiemann Chem Pharm Fab Process for the production of basic substituted salicylamide-O-acetic acid esters
US3347860A (en) * 1964-07-31 1967-10-17 Kyorin Seiyaku Kk Bis-(phenoxyacetyl)-piperazines
US4350692A (en) * 1976-06-03 1982-09-21 Fujisawa Pharmaceutical Co., Ltd. 3,7-Disubstituted-3-cephem-4-carboxylic acids
US6358994B1 (en) * 1997-08-06 2002-03-19 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
WO2002032901A2 (en) * 2000-10-19 2002-04-25 Pfizer Products Inc. Bridged piperazine derivatives
US6395897B1 (en) * 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
WO2003000698A1 (en) * 2001-06-22 2003-01-03 Suntory Limited β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING
EP1295867A1 (en) * 2000-06-28 2003-03-26 Takeda Chemical Industries, Ltd. Biphenyl compound
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
US20050192282A1 (en) * 2004-02-06 2005-09-01 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
EP1849766A1 (en) * 2004-12-27 2007-10-31 Suntory Limited Beta-benzyloxyaspartic acid derivative having two substituents on benzene ring
WO2009124371A2 (en) * 2008-04-09 2009-10-15 Ems S. A. Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
WO2009138714A1 (en) * 2008-05-16 2009-11-19 Avecia Biologics Limited Purification process for antibody fragments using derivatized triazines as affinity ligands
WO2009154739A2 (en) * 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE135638C (en) *
DE1126373B (en) * 1957-03-04 1962-03-29 Thiemann Chem Pharm Fab Process for the preparation of salicylamide-O-acetic acid amides
DE1212955B (en) * 1961-12-06 1966-03-24 Thiemann Chem Pharm Fab Process for the production of basic substituted salicylamide-O-acetic acid esters
US3347860A (en) * 1964-07-31 1967-10-17 Kyorin Seiyaku Kk Bis-(phenoxyacetyl)-piperazines
US4350692A (en) * 1976-06-03 1982-09-21 Fujisawa Pharmaceutical Co., Ltd. 3,7-Disubstituted-3-cephem-4-carboxylic acids
US6358994B1 (en) * 1997-08-06 2002-03-19 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
US6395897B1 (en) * 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
EP1295867A1 (en) * 2000-06-28 2003-03-26 Takeda Chemical Industries, Ltd. Biphenyl compound
WO2002032901A2 (en) * 2000-10-19 2002-04-25 Pfizer Products Inc. Bridged piperazine derivatives
WO2003000698A1 (en) * 2001-06-22 2003-01-03 Suntory Limited β-BENZYLOXYASPARTATE DERIVATIVES WITH AMINO GROUP ON BENZENE RING
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
US20050192282A1 (en) * 2004-02-06 2005-09-01 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
EP1849766A1 (en) * 2004-12-27 2007-10-31 Suntory Limited Beta-benzyloxyaspartic acid derivative having two substituents on benzene ring
WO2009124371A2 (en) * 2008-04-09 2009-10-15 Ems S. A. Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these
WO2009138714A1 (en) * 2008-05-16 2009-11-19 Avecia Biologics Limited Purification process for antibody fragments using derivatized triazines as affinity ligands
WO2009154739A2 (en) * 2008-06-17 2009-12-23 Duke University Smoothened receptor modulators

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COPPOLA, G.M. ET AL.: "Synthesis of 4,5-dihydro-1,3-oxazoles and 5,6-dihydro-4H-1,3-oxazines", SYNTHESIS, vol. 1, 1980, pages 63 - 64, XP002658168 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1963, "Derivatives of amino acid", XP002658167, Database accession no. 1963:53044 *
FAHMY H H ET AL: "SYNTHESIS AND EVALUATION OF THE ANALGESIC AND ANTIINFLAMMATORY ACTIVITIES OF O-SUBSTITUTED SALICYLAMIDES", ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY, PUSAN, KR, vol. 24, no. 3, 1 June 2001 (2001-06-01), pages 171 - 179, XP008079141, ISSN: 0253-6269 *
GILBERT J ET AL: "Condensation de l'ester butylbromomalonique avec le salicyclamide", COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L'ACADEMIE DES SCIENCE, vol. 254, 1962, pages 884 - 886, XP009138600, ISSN: 0001-4036 *
HOSOKAMI, T. ET AL.: "Syntheses of 2-(3,4-dimethoxyphenyl)ethylamine derivatives and their antiulcer activities", CHEM. PHARM. BULL., vol. 40, no. 10, 1992, pages 2712 - 2719, XP002658166 *
KLOSA, J.: "Synthese einiger einfacher Derivate der Salicylamid-o-essigsäure // Synthesis of some simple derivatives of 2-(2-carbamoylphenoxy)acetic acid", ARCHIV DER PHARMAZIE UND BERICHTE DER DEUTSCHEN PHARMAZEUTISCHEN GESELLSCHAFT, vol. 288, 1955, pages 389 - 392, XP009138572, ISSN: 0376-0367 *
OSMAN A N ET AL: "Nucleophilic cleavage of 3,5-dioxo-2,3,4,5-tetrahydro-1,4-benzoxazepine", EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES, NATIONAL INFORMATION AND DOCUMENTATION CENTRE (NIDOC), EG, vol. 22, no. 1-4, 1983, pages 1 - 7, XP009138573, ISSN: 0301-5068 *
PONCI, R. ET AL.: "Preparazione e studio dell'attivita fitormonica di acidi ariltioalcanoici e di loro amidi", FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 19, 1964, pages 356 - 376, XP009151655, ISSN: 0430-0920 *
REICH, S.H. ET AL.: "Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: Secondary amide series", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, 1996, pages 2781 - 2794, XP002557981, ISSN: 0022-2623, DOI: 10.1021/JM960093O *
SUZUE ET AL: "Hepatic agents. I. Synthesis of aminoacyl (and hydroxyacyl)aminoacetonitriles", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 16, no. 8, 1 August 1968 (1968-08-01), pages 1417 - 1432, XP002108053, ISSN: 0009-2363 *
WILLIAMS, D.H. ET AL.: "Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 17, 1 September 2009 (2009-09-01), pages 5246 - 5249, XP026458601, ISSN: 0960-894X, [retrieved on 20090625] *

Also Published As

Publication number Publication date
WO2011104307A2 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
WO2011104307A3 (en) Ligands for antibody purification by affinity chromatography
MX2013003182A (en) Purification of antibodies using simulated moving bed chromatography.
CY1122278T1 (en) ANTI IL-36R ANTIBODIES
WO2013138793A3 (en) Affinity reagants for protein purification
HK1185356A1 (en) Ligands for antibody and fc-fusion protein purification by affinity chromatography fc-
WO2013109302A3 (en) Chromatography matrices including novel staphylococcus aureus protein a based ligands
SG162687A1 (en) Caustic stable chromatography ligands
EP2287174B8 (en) Enhanced purification of antibody fragments by apatite chromatography
NZ599323A (en) Affinity ligands and methods for protein purification
UA115402C2 (en) CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3
WO2009026117A3 (en) Novel compounds
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
MX354243B (en) Antibody polypeptides that antagonize cd40.
AU2009282234A8 (en) Methods for purifying antibodies using protein A affinity chromatography
WO2013177115A3 (en) Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
MX356337B (en) Antibodies against human csf-1r and uses thereof.
BR112014000352A2 (en) method of purifying a fc-fc protein, fc proteins containing purified fc, purified tnfr: fc, and highly purified tnfr: fc
NZ621170A (en) Anti-human cd52 immunoglobulins
MY162791A (en) Anti-il-23 antibodies
MX355255B (en) Fc VARIANTS AND METHODS FOR THEIR PRODUCTION.
WO2011133886A3 (en) Production of heteromultimeric proteins
WO2011130434A3 (en) Antibodies that bind human cd27 and uses thereof
EP2265129A4 (en) Chromatography purification of antibodies
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
SG178886A1 (en) Humanized anti-cdcp1 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11704633

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11704633

Country of ref document: EP

Kind code of ref document: A2